HealthXellSmart Says It Completed Enrollment in Phase II Parkinson’s TrialBy Naomi CalderOct 18, 2026, 4:46 AM UTC
BusinessUnum Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with Seattle GeneticsBy Nasdaq OMXApr 3, 2018, 9:00 PM UTC
BusinessUnum Therapeutics Announces Pricing of Initial Public OfferingBy Nasdaq OMXMar 29, 2018, 1:35 AM UTC
BusinessThe Alliance for Regenerative Medicine Releases Complete Agenda for Sixth Annual Cell & Gene Therapy Investor DayBy Nasdaq OMXMar 28, 2018, 2:47 PM UTC
BusinessAdaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business UpdateBy Nasdaq OMXMar 15, 2018, 11:30 AM UTC
BusinessAdaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cellsBy Nasdaq OMXMar 15, 2018, 11:30 AM UTC
BusinessAdaptimmune to Report Fourth Quarter / Full Year 2017 Financial Results and Business Update on Thursday March 15, 2018By Nasdaq OMXMar 5, 2018, 5:12 PM UTC
